AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16231850
Drug: In-field radiation
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-field radiation therapy (RT)
Trial: 16231850
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell transplantation and cisplatin- and MOPP-containing therapies
Trial: 10071983
Drug: Etoposide (VP16)
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide (VP16) at various dose regimens (30 to 200 mg, infusion times 0.5 to 2 h)
Trial: 7985891
Drug: Procollagen III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procollagen III levels of 1.75 U/mL or more on day 3
Trial: 7985891
Drug: Procollagen III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procollagen III levels of 1.75 U/mL or more on day 7
Trial: 7985891
Drug: Procollagen III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procollagen III levels of 1.75 U/mL or more on day 14
Trial: 1665493
Drug: AIO chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIO chemotherapy (A, 50 mg/m2 on day 1; I, 2 g/m2 on days 1-3; O, 2 mg on day 1) alternating with cisplatin (90 mg/m2 on day 1) and etoposide (150 mg/m2 on days 1-3)
Trial: 1665493
Drug: AIO chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIO chemotherapy (A, Adriamycin 25 mg/m2 on days 1 + 2; I, ifosfamide 2 g/m2 on days 1-5; O, vincristine 2 mg on day 1)
Trial: 6851037
Drug: i.v. atenolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. atenolol followed by oral treatment for 10 days
Trial: 30926371
Drug: Walnut oral
RxNorm normalized name: Almond/Hazelnut/Pistachio/Walnut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut oral immunotherapy
Trial: 24535791
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (levobupivacaine) with 20 mL 0.25% levobupivacaine and 40 mg methylprednisolone
Trial: 24535791
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (bupivacaine) with 20 mL 0.25% bupivacaine and 40 mg methylprednisolone
Trial: 24535791
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (control) with 20 mL physiological saline
Trial: 22334121
Drug: Intravenous Δ⁹-THC
RxNorm normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Δ⁹-THC (0.015 mg/kg)
Trial: 22334121
Drug: Intravenous Δ⁹-THC
RxNorm normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Δ⁹-THC (0.03 mg/kg)
Trial: 17932908
Drug: Subcutaneous interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous interleukin-2 9 million IU daily
Trial: 17932908
Drug: Cytokine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine treatments (interferon-alfa and interleukin-2)
Trial: 17932908
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate 200 mg daily
Trial: 12414028
Drug: Intravenous crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous crystalloid fluids
Trial: 1983780
Drug: ICI 118,551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118,551 (50 mg)
Trial: 1983780
Drug: Diazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (2 mg)
Trial: 7191779
Drug: Combination cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination cyclophosphamide, doxorubicin, and cis-dichlorodiammineplatinum(II) (CAP)
Trial: 30343508
Drug: Tadalafil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (40 mg, single daily dose)
Trial: 30343508
Drug: Sildenafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (20 mg t.i.d.)
Trial: 30343508
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (sildenafil and tadalafil)
Trial: 17575230
Drug: Pemetrexed 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 600 mg/m2 (P600 arm)
Trial: 17575230
Drug: Pemetrexed 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 900 mg/m2 (P900 arm)
Trial: 9626829
Drug: Eptifibatide therapy
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide therapy (135-microg/kg bolus/0.5-microg/kg per min infusion or 135-microg/kg bolus/0.75-microg/kg per min infusion)
Trial: 9626829
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo bolus/placebo infusion)
Trial: 9626829
Drug: PTCR within
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTCR within 24 h of thrombolytic therapy
Trial: 9626829
Drug: Larger heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger heparin doses during PTCR
Trial: 810648
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with antirheumatic drugs
Trial: 810648
Drug: D-penicillamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine and gold treatment
Trial: 19222841
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vardenafil administered orally twice a day for 12 weeks
Trial: 19222841
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally twice a day for 12 weeks
Trial: 11006204
Drug: 1% nitroprusside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% nitroprusside gel (5 mg)
Trial: 11006204
Drug: 2% nitroprusside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% nitroprusside gel (10 mg)
Trial: 9182442
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy with cisplatin, methotrexate, and vinblastine (CMV) after TUR, aiming for vesical preservation (Arm A, n = 20)
Trial: 9182442
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with CMV after TUR followed by cystectomy (Arm B, n = 17)
Trial: 8374255
Drug: Torasemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (20 mg/day)
Trial: 8374255
Drug: Furosemide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (50 mg/day)
Trial: 24935075
Drug: Senior work-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senior work-up assessment and treatment (SWAT) model of care
Trial: 20541900
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine patches (5, 10, and 20 microg/hour)
Trial: 20541900
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (200 and 400 microg tablets)
Trial: 18175753
Drug: Daily chocolate
RxNorm normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily chocolate consumption (>=1 time/d)
Trial: 10935148
Drug: Neuroleptanalgesia (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptanalgesia (0.025 mg fentanyl and 1.25 mg droperidol)
Trial: 10935148
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg initial dose, followed by 5 mg every 4 hours)
Trial: 3515526
Drug: Enteric-coated naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated naproxen tablets (500 mg)
Trial: 3515526
Drug: Plain naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain naproxen tablets (500 mg)
Trial: 27107490
Drug: ICS plus
RxNorm normalized name: Nubasics Plus Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS plus theophylline 100 mg bid
Trial: 15649831
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (manual acupuncture at Y point on the neck, 4 sessions over 2 weeks)
Trial: 2598986
Drug: Cimetropium bromide
RxNorm normalized name: cimetropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetropium bromide (5 mg.h‐1)
Trial: 2598986
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion with caerulein (10‐40 ng.kg‐1.h‐1)
Trial: 16115390
Drug: Theophylline 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 0.2 g twice a day for one month (group CA)
Trial: 31418538
Drug: Rolapitant (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolapitant (single dose range, 9-180 mg)
Trial: 28273591
Drug: Nutrition education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition education intervention for caregivers (initial sessions and monthly monitoring for 6 months)
Trial: 21261971
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment of MTrPs including manual compression, manual stretching, intermittent cold application, home exercises, and ergonomic advice.
Trial: 21261971
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment of MTrPs.
Trial: 27936169
Drug: Control supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control supplements
Trial: 11726005
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (25-100 mg/d)
Trial: 29649002
Drug: Baricitinib treatment
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib treatment
Trial: 27141849
Drug: Chemical 'cold-like'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical 'cold-like' counter-irritation with 40% L-menthol and 10% trans-cinnamaldehyde
Trial: 12548508
Drug: Tacrolimus, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus, 20 ng/mL, plus Plasma‐lyte A liver flush solution
Trial: 3512622
Drug: Fluspirilene (23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluspirilene (23 mg/week for men, 13 mg/week for women)
Trial: 20051119
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual in primary care.
Trial: 18978566
Drug: Paclitaxel 230
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 230 mg/m followed by cisplatin 75 mg/m on day 1 every 21 days, with granulocyte colony stimulating factor 5 microg/kg/d beginning on day 3 of each cycle
Trial: 12436430
Drug: Decongestive lymphatic
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestive lymphatic therapy (DLT) with adjunctive intermittent pneumatic compression (IPC)
Trial: 12436430
Drug: Decongestive lymphatic
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestive lymphatic therapy (DLT) alone
Trial: 11874940
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg pioglitazone
Trial: 9521337
Drug: Intravenous ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbate (vitamin C)
Trial: 26618470
Drug: Calcium Hydroxylapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Hydroxylapatite (CaHA) treatment
Trial: 26618470
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment until end of study)
Trial: 23551070
Drug: 24 IU
RxNorm normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24 IU intranasal oxytocin (OXT)
Trial: 16826364
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (400-1,200 IU per day) with calcium (800-1,500 mg per day)
Trial: 12627044
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA), 5 mg/day for 14 days (days 12-25)
Trial: 12627044
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA), 10 mg/day for 14 days (days 12-25)
Trial: 12627044
Drug: Dydrogesterone, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone, 20 mg/day for 14 days (days 12-25)
Trial: 8239616
Drug: High-dose mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose mefloquine (25 mg/kg)
Trial: 8239616
Drug: Conventional mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional mefloquine (15 mg/kg)
Trial: 22961024
Drug: Daily disinfection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disinfection of high-touch surfaces
Trial: 21041348
Drug: Telehealth intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telehealth intervention (online multifamily psychoeducational therapy)
Trial: 21041348
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (treatment as usual)
Trial: 16052393
Drug: Dalteparin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (low molecular weight heparin) administered immediately after cesarean section until mobilization
Trial: 8746864
Drug: Drug trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug trials conducted by hospitals
Trial: 29943518
Drug: Standard Crisis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Crisis Response Plan (treatment as usual)
Trial: 26364288
Drug: Continuing clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing clopidogrel 75 mg daily (extended‐dual antiplatelet therapy, DAPT, group)
Trial: 26364288
Drug: Discontinuing clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuing clopidogrel (aspirin group)
Trial: 26364288
Drug: Continuing clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing clopidogrel 75 mg daily (extended‐DAPT group)
Trial: 23035060
Drug: Bilateral arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral arm ischemic preconditioning (BAIPC), 5 brief cycles of ischemia followed by reperfusion, performed twice daily over 300 days.
Trial: 18846366
Drug: Alcohol (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (low dose: 0.12 g/kg for women, 0.14 g/kg for men)
Trial: 18846366
Drug: Alcohol (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (high dose: 0.37 g/kg for women, 0.42 g/kg for men)
Trial: 18437797
Drug: Early placed
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early placed implants
Trial: 11586014
Drug: Combination product
RxNorm normalized name: Drug-device combination product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination product of calcipotriol and betamethasone dipropionate
Trial: 11586014
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments except for the vehicle
Trial: 9676347
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release pellets (500 mg theophylline)
Trial: 9676347
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion (350 mg theophylline over 8 h)
Trial: 31997236
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (CM) treatment with Huoxue Xiaoyi Granule before ovulation and Bushen Zhuyun Granule after ovulation for 6 menstrual cycles.
Trial: 31997236
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control group receiving placebo treatment for 6 menstrual cycles.
Trial: 31997236
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (CM) treatment.
Trial: 25231512
Drug: ACT-280778 10
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-280778 10 mg
Trial: 19546359
Drug: Weekly L-AMB
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly L-AMB dosing (7.5 mg/kg)
Trial: 19546359
Drug: Single L-AMB
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single L-AMB dose (15 mg/kg)
Trial: 19546359
Drug: Daily L-AMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily L-AMB dosing (1 mg/kg)
Trial: 19546359
Drug: Overall infusion-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall infusion-related reactions
Trial: 18322594
Drug: 90 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 micrograms recombinant hepatitis B vaccine + IFN alpha 1b 50 micrograms 3 times a week for 24 weeks
Trial: 18322594
Drug: 60 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 micrograms recombinant hepatitis B vaccine + IFN alpha 1b 50 micrograms 3 times a week for 24 weeks
Trial: 8549061
Drug: Acute caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute caffeine ingestion (250 mg)
Trial: 28277054
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for erythema migrans (specific regimens not detailed in the abstract)
Trial: 28277054
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for erythema migrans
Trial: 23835707
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m² on day 1 of 21-day cycles; n = 359)
Trial: 21736786
Drug: Exercise-induced dehydration
RxNorm normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise-induced dehydration plus a diuretic (DD; 40 mg furosemide)
Trial: 19756431
Drug: Response evaluation
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response evaluation or prediction after neoadjuvant chemotherapy
Trial: 22541039
Drug: Treatment responders
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment responders
Trial: 15305227
Drug: 1,000 mU/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mU/l prolactin
Trial: 15305227
Drug: 100 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ng/ml leptin
Trial: 24769014
Drug: Lenalidomide (LEN)
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide (LEN) maintenance therapy, 10 mg daily, given on days 1 to 21 of 28-day cycles for 12 months after alloHCT.
Trial: 19948383
Drug: Oxycodone 20mg
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 20mg
Trial: 19948383
Drug: Oxycodone 0mg
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 0mg (placebo)
Trial: 11888836
Drug: Two daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two daily subcutaneous injections of hexarelin (1.5 microg/kg)
Trial: 11888836
Drug: Three daily
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three daily subcutaneous injections of hexarelin (1.5 microg/kg)
Trial: 11888836
Drug: Intravenous hexarelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hexarelin (1 microg/kg) at the end of each 24-h sampling period
Trial: 11888836
Drug: Prior hexarelin
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior hexarelin administration
Trial: 10442376
Drug: UFT 300
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 300 mg/m2 plus calcium folinate 90 mg (divided into three doses per day)
Trial: 10442376
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel starting at 50 mg/m2, escalated in 10 mg/m2 steps